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Metastasis is powered by disseminated cancer cells that re-create a full-fledged tumor in unwelcoming
tissues, away from the primary site. How cancer cells moving from a tumor into the circulation manage to
infiltrate distant organs and initiate metastatic growth is of interest to cancer biologists and clinical oncolo-
gists alike. Recent findings have started to define the sources, phenotypic properties, hosting niches, and
signaling pathways that support the survival, self-renewal, dormancy, and reactivation of cancer cells that
initiate metastasis: metastatic stem cells. By dissecting the biology of this process, vulnerabilities are being
exposed that could be exploited to prevent metastasis.Introduction
Metastasis results from disseminated cancer cells that reinitiate
a full-fledged tumor. Cancer cells may leave tumors relentlessly,
only to perish en masse while attempting to settle in distant
tissues. Those that survive the ordeal may remain alive for
decades but still fail to form clinically manifest lesions (Braun
et al., 2005; Janni et al., 2011). Yet when metastasis occurs, it
creates complications that account for the vast majority of
deaths from cancer. Cancer cells that succeed at this task
possess not only the attributes of tumor-initiating cells, or
cancer stem cells (CSCs), but also the ability to exert this capac-
ity under harshly adverse conditions. Metastasis therefore is
driven by CSCs at their best—or at their worst, depending on
your perspective.
Insights into the identity, behavior, and needs of cancer cells
that have thecapacity to initiatemetastasis are coming from three
fronts. First, the existence of CSCs originally described in tumors
of hematopoietic origin (Bonnet and Dick, 1997; Lapidot et al.,
1994) has now been established in many solid tumors including
those arising in the brain (Chen et al., 2012; Singh et al., 2004),
colon (Dalerba et al., 2007; Merlos-Sua´rez et al., 2011; O’Brien
et al., 2007;Ricci-Vitiani et al., 2007;Schepers et al., 2012), breast
(Al-Hajj et al., 2003; Mani et al., 2008; Pece et al., 2010), skin
(Driessens et al., 2012; Malanchi et al., 2008), prostate (Wang
et al., 2009), and pancreas (Hermann et al., 2007; Li et al.,
2007a). These findings have pushed the debate on the nature of
cancer stem cells from conjecture to more concretion, though
many questions remain. Second, the identification of clinically
relevant metastasis genes and functions has improved the bio-
logical conceptualization of metastasis and its distinct phases
(Nguyen et al., 2009a; Valastyan and Weinberg, 2011). Third,
high-resolution sequencing of tumor samples and other ap-
proaches provide evidence that metastasis relies less on driver
mutations than on epigenetic amplification of cell survival and
self-renewal mechanisms (Vanharanta and Massague´, 2013).306 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.Building on this progress, here we review the current under-
standing of sources, lethal challenges, hosting niches, and vital
pathways that enable the persistence and progression of meta-
static stem cells. At the outset we stress that this is an emerging
field and that, because of this, many aspects are derived from
models that recapitulate the process imperfectly or are based
on inference from clinical data. Nonetheless, the extant evidence
provides a useful framework for the analysis of the problem,
with the understanding that much work still needs to be done
to challenge or support these ideas.
Deadly Seeds Left Behind
When a surgeon removes a primary tumor mass with perfect
marginal clearance, the disease does not necessarily go away.
At diagnosis a tumor may have already shed thousands of can-
cer cells, starting when the still-incipient lesion broke through
basal lamina and malignant cells reached the bloodstream
(Figure 1). These disseminated tumor cells (DTCs) are found in
bone marrow of breast cancer patients who have no signs of
overt metastasis (Braun et al., 2005), have small primary tumors
(Klein, 2009; Pantel et al., 2009), or have been treated and are
disease-free by every other criteria (Pantel et al., 2009; Pantel
and Brakenhoff, 2004).
Studies on DTCs have been largely based on the analysis of
bone marrow samples. However, the presence of bone marrow
DTCs is predictive of metastasis not only in bone but also in liver,
lung, and brain (Braun et al., 2005). This also applies to diseases
like colorectal cancer that do not normally metastasize to bone
(Pantel and Brakenhoff, 2004). Though little is known about the
capacity of other organs to host DTCs, case reports on liver,
kidney, and heart transplants that conferred metastatic mela-
noma to recipients argue that these organs can harbor latent
DTCs (Stephens et al., 2000; Strauss and Thomas, 2010).
Systemic anticancer therapy can eliminate DTCs, but often
not fully (Figure 1; Becker et al., 2006; Fehm et al., 2006). The
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Figure 1. Deadly Seeds Left Behind in a
Typical Course of Metastatic Cancer
At diagnosis a primary tumor (a carcinoma of the
lung or breast in this example) may have already
seeded distant organs with cancer cells, including
cells with tumor-initiating capacity that are defined
here as metastatic stem cells (MetSCs). After
diagnosis, the primary tumor may be removed by
surgery and irradiation, and disseminated cancer
cells may be eliminated by systemic chemo-
therapy, leading to a cure. Alternatively, residual
MetSCs may remain in a latent state, eventually
giving rise to overt metastasis. New rounds of
therapy may then induce regression of the
metastatic lesions, but chemoresistant MetSCs
selected during each round of treatment may
eventually give rise to uncontrollable metastasis.
This process is responsible for 90%of deaths from
cancer.
Cell Stem Cell
Reviewpresence of residual DTCs in bone marrow after adjuvant ther-
apy is predictive of subsequent recurrence and poor survival
(Janni et al., 2011). Several factors provide DTCs with a chance
to persist. In the bone marrow at least, solitary DTCs are largely
in a nonproliferative state that is not susceptible to antimitotic
therapy (Mu¨ller et al., 2005; Naumov et al., 2003). Moreover,
DTC populations may differ from the bulk cancer cell population
in terms of drug sensitivity (Holohan et al., 2013). DTCs may
additionally benefit from stromal signals that protect them from
genotoxic stress (Acharyya et al., 2012). Sometimes DTCs thrive
while the primary tumor withers, giving rise tometastatic cancers
of unknown primary site (Massard et al., 2011).
MetSCs: Definition and Origins
Metastasis involves invasion and intravasation of cancer cells
from the primary tumor, dissemination through the circulation,
extravasation in different organs, survival on arrival, settlement
into latency, reactivation, and overt colonization with generation
of a newmacroscopic tumor (Figure 2). Migrant cancer cells that
manage to settle in a distant tissue become DTCs that can give
rise to metastasis. This does not make every DTC a potential
metastasis-initiating cell. Some DTCs may have progressed
too far down a differentiation or senescence path and do not
stand a chance of reinitiating tumor growth.
With the term metastatic stem cell (MetSC), we refer here to
anyDTC that is capable of reinitiatingmacroscopic tumor growth
in a distant tissue. This definition is independent of the origin or
phenotypic characteristics (e.g., marker genes) of these cells
and does not necessarily imply the presence of other functional
features (e.g., chemoresistance). MetSCs may already exist in
the primary tumor with the necessary traits to overcome the
bottlenecks of the metastatic process, or, alternatively, may
derive from DTCs that reacquire the competence to initiate
tumor growth after a period of indolence (Figure 1). Investigation
of these two possible sources by functional analysis of MetSCsCell Stem Cellin clinical DTC populations remains
elusive. So far, studies have been limited
to associations between numbers of
DTCs and risk of metastasis (Pantel
et al., 2008, 2009). Accurate analysis of
the lineage and functional relationshipsof MetSCs to CSCs in primary tumors and to DTCs in distant tis-
sues awaits the development of better models and technology to
track and interrogate these cell populations. However, evidence
for the two alternative sources of MetSCs can be found at least in
model systems.
MetSCs by Birthright
It is increasingly clear that the cell heterogeneity characteristic of
many cancer types results from a hierarchical organization that
resembles that of the tissue of origin (Figure 2). CSCs comprise
the apex of this hierarchy and appear to be the phenotypic and
functional equivalents of normal stem cells harboring oncogenic
mutations. CSCs in primary tumors self-renew their own popula-
tion and can generate short-lived progeny (i.e., transit-amplifying
cells and more differentiated descendants). Recent lineage
tracing experiments in mouse models provide genetic evidence
that primary tumors of the brain, colon, and skin comply with this
organization (Chen et al., 2012; Driessens et al., 2012; Nakanishi
et al., 2013; Schepers et al., 2012). It remains to be determined
whether metastases arising from these tumors retain a similar
hierarchy. Nevertheless, because the long-term growth capabil-
ities of these and other cancers relies on CSCs, the idea that
MetSCs in these cases may be primary CSCs that resume their
regenerative potential at metastatic sites is of interest (Figure 2).
Circumstantial evidence in favor of this idea comes from the
clinic. High expression of adult stem cell markers in primary
tumors is associated with poor prognosis andmetastatic relapse
(Dalerba et al., 2011; Merlos-Sua´rez et al., 2011; Pece et al.,
2010). Cell populations capable of generating metastasis when
transplanted into mice can be isolated from primary tumor sam-
ples via stem cell marker genes (Hermann et al., 2007; Malanchi
et al., 2012; Pang et al., 2010). Cancer cells expressing stem
cell markers have been detected in the blood of breast cancer
patients, and when inoculated into immunodeficient mice these
cells generated bone, liver, and lung metastases (Baccelli
et al., 2013).14, March 6, 2014 ª2014 Elsevier Inc. 307
Figure 2. Sources, Dissemination,
Dormancy, and Outgrowth of MetSCs
Several types of cancer display a hierarchical
organization with CSCs being the only cell type
with long-term self-renewal potential. The progeny
of CSCs—the transit-amplifying progenitors (TAs)
and their differentiated derivatives—are short lived
and have a lower tumorigenic potential. Conver-
sion of non-CSCs into CSCs occurs in certain
types of cancer and can be triggered by cytokines
and stress conditions. CSCs interact with micro-
environmental niches that sustain the tumor-
perpetuating potential of the cells. Both CSCs and
non-CSCs can display migratory behavior at the
invasive front of primary tumors, frequently asso-
ciated with an EMT. Intravasation, circulation,
and extravasation of cancer cells in these various
states can occur continuously until the primary
tumor is removed. Survival of disseminated cancer
cells at distant sites is a limiting step, because
the vast majority of infiltrating cancer cells die. The
survivors that are endowed with tumor-initiating
capacity constitute MetSCs. Cells that had previ-
ously undergone an EMT must reacquire epithelial
traits and coopt a supportive stromal niche in
order to thrive in the new environment. Addi-
tionally, disseminated non-CSCs may convert into
MetSCs through still poorly understood processes
of phenotypic plasticity. MetSCs may generate
progeny and give rise to overt metastasis right
after infiltrating the host tissue. More frequently,
however, disseminated cancer cells enter a dormant state that can last for decades and is largely resistant to current therapies. Upon exit from quiescence,
MetSCs may regenerate their lineage in the host organ and release metastatic progeny into the circulation to start secondary lesions in the same or other
organs. Treatment of overt metastasis seldom results in eradication of the disease, because residual MetSCs frequently regenerate the tumor after each drug
treatment cycle.
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ship between MetSCs, primary tumor CSCs, and normal stem
cells comes from colorectal cancer. Studies with genetic mouse
models indicate that upon acquiring activating mutations in the
WNT pathway, intestinal stem cells generate adenomas (Barker
et al., 2009). Lineage-tracing analysis shows that a population of
stem cells that resembles those present in normal intestinal
mucosa sustains the long-term growth of these benign lesions
while generating short-lived progeny that undergo differentiation
(Kozar et al., 2013; Nakanishi et al., 2013; Schepers et al., 2012).
This hierarchical organization appears to be retained in late-
stage colorectal cancers (Dalerba et al., 2011; Merlos-Sua´rez
et al., 2011; Vermeulen et al., 2008) and even liver metastases
contain stem- and differentiated-like tumor cells (Merlos-Sua´rez
et al., 2011). Clonal analysis of human colorectal cancer sam-
ples upon lentiviral marking of tumor cell populations demon-
strates that metastases arise from primary tumor cells that
display long-term self-renewal capacity and are quiescent and
resistant to chemotherapy (Dieter et al., 2011; Kreso et al.,
2013).
Certain cancers such as melanoma do not appear to rely on a
hierarchical organization (Meacham and Morrison, 2013; Quin-
tana et al., 2010). However, these tumors still contain MetSCs
as defined here, as cells that hijack stem cell traits that facilitate
regeneration of the disease at a distant site.
MetSCs by Reeducation
An alternative route to MetSC status is based on regaining
tumor-initiating capacity through phenotypic plasticity (Fig-
ure 2). This possibility is suggested by several observations.
In cell line xenograft models, breast cancer stem-like cells308 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.can arise from non-stem populations as a result of stochastic
transitions between both states (Gupta et al., 2011). Certain
cytokines can stimulate the expression of CSC features. For
example, hepatocyte growth factor from stromal fibroblasts
potentiates WNT/b-catenin signaling to enhance the stem cell
potential of colorectal cancer cells (Vermeulen et al., 2010).
Transforming growth factor b (TGF-b) enhances the CSC
potential in glioblastoma (Anido et al., 2010) and collaborates
with WNT to promote CSC potential in breast cancer cells
(Scheel et al., 2011).
Gains in stem-like features are sometimes accompanied by
an epithelial to mesenchymal transition (EMT) (Figure 2; Mea-
cham and Morrison, 2013; Nieto, 2013; Thiery et al., 2009;
Valastyan and Weinberg, 2011). EMT is a vital process during
embryogenesis, particularly in steps that involve tissue invasion
such as gastrulation or neural crest migrations (Nieto, 2013). At
its core, the EMT is driven by a network of transcription factors
including Snail1, Snail2, and Snail3, ZEB1 and ZEB2 (zinc-finger
E-box binding factor), Twist, and others (Nieto, 2013). Epige-
netic changes underlie the EMT (Tam and Weinberg, 2013). In
cancers arising from epithelial tissues, the carcinoma cells are
embedded within glandular structures that restrict their migra-
tion. In skin and breast carcinoma models, tumor-derived
TGF-b stimulates EMT (Oft et al., 1996; Xu et al., 2009). By
undergoing an EMT, carcinoma cells at the tumor invasive front
lose cell-to-cell adhesion and apical-basal polarity and gain
migratory behavior to surpass these barriers. Remarkably, the
enforced expression of EMT transcription factors in breast and
pancreatic cancer cells additionally confers stem-like features
upon them (Mani et al., 2008; Scheel et al., 2011; Wellner
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coexpressed in circulating tumor cells from patients with metas-
tasis (Aktas et al., 2009; Baccelli et al., 2013; Yu et al., 2012,
2013).
To be clear, though, CSCs exist both in epithelial and mesen-
chymal states (Liu et al., 2014). Although EMT favors the emigra-
tion of carcinoma cells from the primary tumor, it inhibits cell
proliferation and interferes with the initiation of metastatic
outgrowth (Ocan˜a et al., 2012; Stankic et al., 2013; Tsai et al.,
2012; Celia`-Terrassa et al., 2012). As we discuss later, MetSCs
that have undergone an EMTmust reacquire an epithelial pheno-
type in order to resume growth at the metastatic site.
Sources of Metastatic Traits
Regardless of their origin, cancer stem cells require additional
traits in order to successfully express metastasis-initiating po-
tential. For example, xenotransplantation studies of stage IIIB/C
human melanomas showed that most samples contained cells
that could initiate subcutaneous lesions in mice. However,
distant metastasis occurred only with transplanted tumors
from patients with metastatic melanoma. These differences
correlated with the presence of circulating tumor cells in the
blood of the recipient mice, consistent with the idea that
melanoma-initiating cells require specific traits, such as an ability
to enter into and survive in the circulation, in order tometastasize
(Quintana et al., 2012).
The question of whether metastatic traits are directly con-
ferred by mutations in specific ‘‘metastasis genes’’ has long
been debated. Mutations affecting key cell proliferation, sur-
vival, and self-renewal pathways clearly act as ‘‘drivers’’ of
tumor initiation (Vogelstein et al., 2013). Further tumor progres-
sion is accompanied with widespread genetic heterogeneity in
the cancer cell population (Burrell et al., 2013). A reasonable
expectation would be that metastasis-driving mutations are
contained within this heterogeneity (Fidler, 2003). However,
large-scale genome sequencing of human tumors found little
evidence for recurrent metastasis-restricted mutations (Bozic
et al., 2010; Yachida et al., 2010), other than mutations in classic
initiator oncogenes that are further enriched in metastatic
lesions (Campbell et al., 2010; Ding et al., 2010). Metastasis
therefore cannot easily be ascribed to recurrent mutations in
‘‘metastasis-driver’’ genes.
Mutations in epigenetic control pathways are another matter.
Mutations in epigenetic regulators or in metabolic pathways
that support their function (such as that controlled by isocitrate
dehydrogenases IDH1 and IDH2) can lock transcriptomic out-
puts in altered states that favor the emergence and selection
of tumor progression traits. Because this literature is not the pri-
mary focus of this review, we will refer readers to recent reviews
for further reading on these topics (Shen and Laird, 2013; Ward
and Thompson, 2012). In the context of metastatic progression,
the pleiotropic impact of these mutations on transcriptional
output provides cancer cell populations with opportunities
to evolve under the selective pressure of invaded microen-
vironments. Such mutations probably play a prominent role in
favoring the emergence of metastatic traits (Vanharanta and
Massague´, 2013). The mutant genes are not direct oncogenic
drivers in the classical sense; rather, they channel the effect
through imbalances in cell growth, invasiveness, and/or self-renewal pathways. For instance, in renal cell carcinomas driven
by the VHL-HIF2a pathway, alterations in methylation of histone
H3K27 and DNA expand the transcriptional output of this
pathway to facilitate the expression ofCXCR4 andCYTIP. These
twoHIF2a target genes are not required for primary tumor forma-
tion but are powerful enhancers of metastasis (Vanharanta
et al., 2013). Suppressed expression of the differentiation factors
Nkx2-1, GATA6, and HOPX, probably as a result of epigenetic
silencing, enhancesmetastasis in non-small-cell lung carcinoma
(Cheung et al., 2013; Winslow et al., 2011). Alterations in mRNA
processing, noncoding RNAs, and the translational machinery
can also alter the output of cancer cell pathways to favor the
emergence of metastatic traits (Di Leva et al., 2014; Guo et al.,
2012; Moore and Proudfoot, 2009; Pencheva and Tavazoie,
2013; Valastyan et al., 2011). Future genome-wide sequencing
studies may yet reveal mutations that directly and specifically
drive metastasis and not primary tumor formation. However,
the evidence to date favors the conclusion that mutations giving
rise to pleiotropic epigenetic alterations are a major source of
selectable metastatic traits.
Metastatic Selection in Primary Tumors
Metastasis-seeding traits become relevant as soon as cancer
cells reach distant organs. The traits that give cancer cells an
edge at surviving on arrival in distant organs must therefore
be acquired before dissemination. That such traits are present
in primary tumors is suggested by the repeated identification
of mediators of dissemination and metastatic seeding among
gene expression signatures in primary tumors that predict
relapse (Bos et al., 2009; Calo´n et al., 2012; Cheung et al.,
2013; Guo et al., 2012; Hu et al., 2009; Minn et al., 2005; Nguyen
et al., 2009b; Tavazoie et al., 2008; Vanharanta et al., 2013;
Zhang et al., 2013a). These traits are distinct from those that
mediate overt metastatic colonization months or years later
(Eisinger-Mathason et al., 2013; Minn et al., 2005; Nguyen
et al., 2009a; Valastyan andWeinberg, 2011). Colonization traits,
such as the ability of DTCs in the bone marrow to coopt osteo-
clasts for osteolytic metastasis (Guise, 2010; Kang et al., 2003;
Waning et al., 2013), are not required for the initial survival of
DTCs. Their acquisition can probably wait.
A likely site for selection of metastatic traits in primary tumors
is at the invasive front, the intersection of an advancing tumor
mass and the surrounding stroma. Cancer cells that have over-
come their own cell-autonomous oncogenic stresses engage
in invasive behavior that exposes them to a reactive stroma, hyp-
oxia, and immune surveillance (Figure 3A). The invasive front is
rich in tumor-associated macrophages (TAMs), myeloid pro-
genitor cells, cancer-associated fibroblasts (CAFs), and newly
generated blood vessels (Joyce and Pollard, 2009). Wnt, Notch,
TNF-a, TGF-b, and hedgehog cytokines derived from the stroma
are present in invasive fronts. This milieu is thought to support
the survival and fitness of CSCs (Takebe et al., 2011) and may
select for traits that are advantageous to cancer cells not only
locally but also in distant tissues.
In addition to exerting selection for general metastasis-
supporting traits, the primary tumor stroma can also select
for organ-specific seeding traits. This specificity was recently
shown in the case of bone metastatic breast cancer (Zhang
et al., 2013b). A CAF-rich stroma in breast tumors producesCell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc. 309
Figure 3. Selection of Metastatic Traits in
Primary Tumors
(A) Cancer cells at the invasive front of primary
tumors are exposed to the stresses of invading
surrounding tissue, hypoxia, and immune surveil-
lance. Various stromal cell types produce signals
that cancer cells can use for survival, self-renewal,
invasiveness, and migration. Under selective
pressure, these signals skew the heterogeneous
cancer cell population toward a preponderance of
clones that are primed for survival also under
stress of infiltrating distant tissues.
(B) When the stroma of a primary tumor is rich in
cells and signals that resemble those of a partic-
ular distant tissue, cancer cell clones selected in
the primary tumor may be primed to thrive in that
particular tissue. An example is provided by the
ability of a CAF-rich stroma in breast tumors to
select for cancer cell clones that are fittest to
respond to the CAF-derived factors CXCL12 and
IGF1 and thereby are primed for survival in the
CXCL12- and IGF1-rich environment of the bone
marrow. Image adapted from Zhang et al. (2013b).
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cancer clones that are superior at responding to these signals
with activation of the PI3K-AKT survival pathway. Src-high
clones are thereby primed for seeding the bone marrow where
local sources of CXCL12 and IGF1 provide them with a higher
chance of survival (Figure 3B). As a corollary to these findings,
CAF content, CXCL12/IGF1 signaling, and high Src activity in
breast tumors all predict an increased likelihood of bone relapse
in breast cancer patients (Zhang et al., 2009, 2013b).
Cancer cells may leave a primary tumor early and evolve
separately from the tumor. It has been proposed that the parallel
evolution of early disseminated cancer cells over a period
of indolence affords these cells a superior adaptation to their
metastatic microenvironment and a leading role in metastatic
relapse (Klein, 2009). Cancer cell entry into the circulation and
lodging in distant organs can certainly occur after minimal ge-
netic changes (Podsypanina et al., 2008; Schardt et al., 2005).
However, large-scale genome sequencing studies have shown
more similarities than differences between primary tumors and
their metastases, suggesting that most of the genetic changes
required for metastasis accumulate in primary tumors (Yachida
et al., 2010). Actively growing cancer cells in primary tumors
may be more likely to undergo variation for the selection of
metastatic traits than their precociously dispersed, indolent
comrades.310 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.Metastasis Patterns and
Probabilities
The spectrum of organs affected by
metastasis and the latency period be-
tween diagnosis and relapse depend on
the typeof cancer (Hesset al., 2006; Jones
et al., 2008). For example, breast cancer,
lung cancer, and skin melanoma typi-
cally relapse in multiple organs (bones,
lungs, liver, and brain), whereas prostate
carcinoma relapses most aggressively in
bone, ocular melanoma in liver, and sar-
comas in lung. Metastasis typically hasa long latency period in melanoma, sarcoma, prostate cancer,
and luminal breast cancer, but not in lung cancer or basal breast
cancer.
Metastasis is clearly a function of many variables, and in the
process many mediators intervene that increase an always
very small probability of a cancer cell to complete the process.
The dissemination of cancer cells to distant tissues is influenced
by circulation patterns, as is particularly manifest in intestinal
cancers. Colorectal cancer cells enter the mesenteric circulation
that feeds the liver capillary network and provides an ample op-
portunity to infiltrate the hepatic parenchyma. Colorectal cancer
metastasis occurs mostly in the liver, with lung relapse a distant
second. Beyond the passive role of circulation patterns, cancer
cell dissemination is actively influenced by cancer cell-autono-
mous functions (e.g., invadopodia formation), paracrine factors
(e.g., VEGF and EGF family members), proteases (e.g., metal-
loproteinases, cathepsins), recruitment of stromal components
(e.g., tumor-associated macrophages), and interactions with
blood platelets (Bos et al., 2009; Chabottaux et al., 2009; Chen
et al., 2011a; Gay and Felding-Habermann, 2011; Gocheva
et al., 2010; Greenberg et al., 2008; Gupta et al., 2007;
Kim et al., 2009; Labelle et al., 2011; Li et al., 2010; Padua
et al., 2008; Reymond et al., 2013; Rolny et al., 2011; Sonoshita
et al., 2011; Stockmann et al., 2008; Wyckoff et al., 2004, 2007;
Zijlstra et al., 2008).
Figure 4. A Reactive Stroma Kills Infiltrating Cancer Cells
Astrocytes in the brain stroma react to infiltrating breast or lung cancer cells
by expressing plasminogen activator (PA). PA generates plasmin that cleaves
and mobilizes membrane-bound Fas ligand (FasL) from astrocytes. The can-
cer cells succumb to Fas-mediated apoptosis, but can avert this fate by
expressing PA inhibitory serpins. Neuroserpin is normally expressed only in
neurons, which use it for protection against astrocytes reacting to brain injury.
Image adapted from Valiente et al. (2014).
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have yet to be specifically investigated in CSCs, their expression
in primary tumors is associated with metastatic relapse in the
clinic. The association suggests that these mediators are also
relevant to the dissemination of MetSCs or to their establishment
as viable seeds in distant host tissues.
The Metastasis Seeding Bottleneck
The organ distribution pattern of metastatic disease depends
not only on the likelihood thatMetSCswill reach in distant organs
but also on the probability that these cells will survive there
and eventually initiate metastatic outgrowth. On a per cell basis,
this probability is invariably low. The cellular composition, vascu-
larity, immune surveillance, and inflammatory status of the infil-
trated tissues differ sharply from those of the primary tumor
where cancer clonal selection originally took place. Both exper-
imental evidence and clinical observation suggest that circu-
lating cancer cells suffer massive attrition upon infiltrating distant
tissues (Chambers et al., 2002; Fidler, 2003; Nguyen et al.,
2009a). Most cancer cells injected intravenously to flood the
lungs of mice undergo apoptosis within 2 days (Wong et al.,
2001). Most melanoma cells injected intraportally to flood the
liver fail to form micrometastases, and only 0.02% formed mac-
rometastases (Cameron et al., 2000; Luzzi et al., 1998). In exper-
imental systems, circulating cancer cells do worse in metastatic
sites than on reinfiltrating the tumor of origin, a phenomenon
called ‘‘tumor self-seeding’’ (Kim et al., 2009). Thus, no tissue‘‘soil’’ may be welcoming to metastatic seeds, though certain
soils may be less hostile than others.
That only a tiny fraction of disseminated cancer cells initiate
metastatic outgrowth cannot be explained by a scarcity of
CSCs in the population. The frequency of tumor-initiating cells
in different types of cancer may have been underestimated
because of biases imposed by the experimental models (Quin-
tana et al., 2008). Quantitative lineage tracing clonal analysis is
needed to assess the abundance of CSCs in different tumor
types (Clevers, 2011; Meacham and Morrison, 2013; Beck and
Blanpain, 2013). However, in experimental models at least, infil-
trating distant organs is clearly a traumatic experience for CSCs
(Figure 2). Colorectal CSCs can readily reach the liver only to
suffer massive apoptosis (Calo´n et al., 2012), and breast CSCs
that infiltrate the lung parenchyma are eliminated within days
(Malanchi et al., 2012).
Remarkably little is known about what kills cancer cells upon
infiltration of distant organs. A scarcity of survival signals in the
host parenchyma, lack of a supportive stroma, and overexpo-
sure to innate immunity are potential causes (Chambers et al.,
2002; Fidler, 2003; Nguyen et al., 2009a; Schreiber et al.,
2011). Human bone metastasis lesions express the cytokine
TRAIL, which is lethal to breast cancer cells (Zhang et al.,
2009). Cancer cell death on arrival is a general phenomenon
in all organs and is particularly acute in the brain (Heyn et al.,
2006; Kienast et al., 2010; Perera et al., 2012; Steeg et al.,
2011). Recent work in models of brain metastasis from breast
and lung cancers has shown that the brain stroma takes a very
active role in killing the infiltrating cancer cells (Valiente et al.,
2014). In this context, cancer cells exiting from brain capillaries
are confronted by reactive astrocytes that generate plasmin
to mobilize the killer cytokine FasL against the infiltrators. The
metastatic cells can fend off this attack by producing serpin
inhibitors of plasmin generation (Figure 4).
Metastatic Niches
The need to find supportive sites is thought to be important for
disseminated cancer cells. Stem cells in adult tissues reside in
specific sites or ‘‘niches,’’ the cellular and molecular compo-
nents of which regulate the self-renewal potential of stem cells
and their access to differentiation cues. The location and consti-
tution of stem cell niches have been defined in various tissues,
including the intestinal epithelium, hematopoietic bone marrow,
epidermis, and brain (Clevers, 2013; Hsu and Fuchs, 2012;
Moore and Lemischka, 2006; Morrison and Spradling, 2008). In
primary tumors, cancer cells may interact with these native
stem cell niches, but such interactions will cease as cancer cells
leave the tumor (Figure 2). Growing evidence indicates that the
survival and fitness of metastasis-initiating DTCs depend on
specific components of the host environment that play the part
of a niche for these cells.
We use the term ‘‘metastatic niche’’ broadly here to designate
the specific locations, stromal cell types, diffusible signals, and
extracellular matrix proteins that support the survival and self-
renewal of disseminated MetSCs. Three distinct sources of met-
astatic niche functionality can be envisioned (Figure 5): (1) native
stem cell niches that metastatic cells may occupy in the host tis-
sues; (2) niche functions provided by stromal cells not belonging
to stem cell niches; and (3) stem cell niche components that theCell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc. 311
MetSC  
Settlement in
perivascular niche
(e.g., L1CAM ) 
Occupation of native
stem cell niches
(e.g., HSC niche)
Paracrine components
from non-niche cells
(e.g., Periostin)
Autocrine niche
components
(e.g., Tenascin C)
Figure 5. Three Possible Sources of
Metastatic Niche Support
Disseminated cancer cells can obtain stem cell
niche support by occupying native stem cell
niches including perivascular sites by recruiting
stromal cells that produce stem cell niche-like
components or by producing niche components
themselves.
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provided experimental evidence for these sources and a basis
to consider their contributions in human disease.
Niche Locations
Cancer cells that infiltrate distant organs may lodge in random
locations of the invaded parenchyma. However, recent work
provides evidence that DTCs can occupy native stem cell niches
of the host tissue. Prostate cancer cells showed affinity for the
hematopoietic stem cell niche within the bone marrow, where
they may benefit from cues that enhance stem cell properties
and deter differentiation (Shiozawa et al., 2011).
Another location where cancer cells initiate metastatic
outgrowth is around blood capillaries—the perivascular niche.
This niche has been studied as a preferred residence for glioma
stem cells that supplies these cells with hedgehog-, Notch-, and
PI3K-activating signals (Charles and Holland, 2010; Hambard-
zumyan et al., 2008). Breast cancer, lung cancer, and melanoma
cells that infiltrate the brain conspicuously place themselves
around capillaries (Carbonell et al., 2009; Kienast et al., 2010).
The cells proliferate over the coopted vessels, forming a sheath
that eventually becomes multilayered and remodels the capillary
network at the core of the expanding lesion (Figure 6). Recent
work showed that brain metastasis-initiating cells express the
Ig family cell adhesion molecule L1CAM and use it to stretch
over the perivascular basal lamina (Valiente et al., 2014).
L1CAM is normally expressed only in neurons for axon guidance
(Maness and Schachner, 2007). Its expression in many types of
cancer is associated with poor prognosis (Doberstein et al.,
2011; Schro¨der et al., 2009), raising the possibility of a role for
L1CAM in metastasis to other organs besides the brain.
Niche Cells and Cytokines
Stem cell niches are sources of developmental and self-renewal
signals including Wnt, Notch, the TGF-b family, CXCL12/SDF1,
and hedgehog (Clevers, 2013; Hsu and Fuchs, 2012; Moore
and Lemischka, 2006; Morrison and Spradling, 2008). Perhaps
not surprisingly, gene expression profiles of metastatic samples
overlap in the repertoire of activated pathways with those
of adult stem cell niches (Takebe et al., 2011). A source of
these signals in the bone marrow are mesenchymal cells that312 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.produce CXCL12/SDF1 for hematopoi-
etic stem cell maintenance. The cognate
chemokine receptor CXCR4 is frequently
overexpressed in bone metastatic cells
and provides these cells with chemo-
taxis and PI3K-mediated survival signals
(Figure 7; Mu¨ller et al., 2001; Zlotnik
et al., 2011).
Perivascular niches may support
MetSCs by supplying not only attach-ment, oxygen, and nutrients but also paracrine factors from the
activated endothelium, in what is called ‘‘angiocrine’’ stimulation
(Butler et al., 2010). Interestingly, Jagged-1 expression in endo-
thelial cells promotes the CSC phenotype in colorectal cancer
cells (Lu et al., 2013). miR-126, initially identified as a metas-
tasis-suppressor microRNA (Tavazoie et al., 2008), was shown
to inhibit endothelial cell recruitment and thereby suppress
lung metastasis (Png et al., 2012). Endothelial cells also express
various extracellular matrix (ECM) components that promote
metastatic functions in tissue culture (Ghajar et al., 2013). As
metastatic lesions grow, the cancer cells recruit TAMs, myeloid
precursors, and mesenchymal cells that establish paracrine
loops feeding back to the cancer cells with various survival
and self-renewal factors (Figure 7; Acharyya et al., 2012; Calo´n
et al., 2012; Joyce and Pollard, 2009; Vermeulen et al., 2010).
Primary tumors can systemically influence the microenvi-
ronment of distant organs, especially the lungs, to establish a
‘‘premetastatic niche’’ (Kaplan et al., 2005). In mouse models,
breast, lung, and gastrointestinal tumors secrete inflammatory
cytokines and ECM-remodeling enzymes into the circulation.
These factors can induce changes in the lung parenchyma
microenvironment that enhance metastasis initiation as circu-
lating cancer cells arrive in these locations (Kaplan et al., 2005;
Yamamoto et al., 2008).
Niche Extracellular Matrix
The ECM components tenascin C (TNC) and periostin have been
shown to play important roles in the metastatic niche in mouse
models of cancer. TNC is a hexameric glycoprotein that is found
in stem cell niches and supports stem cell functions (von Holst,
2008). TNC expression in breast tumors is associated with
increased risk of lung metastasis (Minn et al., 2005). In xeno-
transplantation models, breast cancer cells that express high
levels of TNC have a distinct advantage at initiating metastases
after extravasating in the lungs (Oskarsson et al., 2011). TNC
regulatesMusashi and other as-yet-unknown factors to enhance
Notch and Wnt signaling in the cancer cells (Figure 7). By
expressing their own TNC, breast cancer cells have a higher
probability of surviving during micrometastatic outgrowth. Myo-
fibroblasts and S100A4+ fibroblasts eventually migrate into the
Figure 6. The Perivascular Niche for Metastasis Initiation
(A) Metastasis-initiating cells (green) exiting from brain capillaries (red) remain tightly associated with the vessels, adhering to and stretching over their abluminal
surface. This interaction is required for metastatic outgrowth. Outgrowth occurs, forming a sheath over the capillary and later a multilayered cell colony.
(B) The axonal guidance cell adhesion receptor L1CAM is aberrantly expressed in tumors, and its expression is associated with relapse. L1CAM in metastasis-
initiating cells (green) that infiltrate the brain mediates their adhesion to capillary basal lamina (magenta). Besides providingMetSCs with mechanochemical cues,
vascular cooption facilitates their access to oxygen and nutrients from the blood supply and to factors from the endothelium and surrounding stroma. Adapted
from Valiente et al. (2014).
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et al., 2011; Oskarsson et al., 2011).
Like TNC, periostin is present in stem cell niches and is
required for the initiation of lung metastasis by breast cancer
cells in mice (Malanchi et al., 2012). Recruited myofibroblasts
are a source of periostin in response to tumor-derived TGF-b.
Periostin binds and presents stromal Wnt ligands to the cancer
cells (Figure 7). TNC and periostin thus enhanceWNT and Notch
signaling to promote the fitness of MetSCs during the initiation of
metastatic colonization. TNC and periostin bind to cell surface
integrins and bind tightly to each other (Kii et al., 2010). The phys-
ical interaction of TNC and periostin in the ECM may underlie a
functional cooperation of these two proteins in stem cell niches
(Oskarsson and Massague´, 2012).
In the course of cancer progression, tumors exhibit increased
stiffness and the ECM is a key mediator of this tissue tension.
Cancer cells respond to tensile forces imposed by a stiff ECM
with activation of focal adhesion kinase (FAK) and PI3K-AKT
and with invasive behavior (Figure 7; Levental et al., 2009). One
enhancer of ECM stiffness is lysyl oxidase (LOX), a collagen
crosslinking enzyme that is induced by hypoxia. LOX expression
contributes to tissue stiffness and myeloid cell attraction
for tumor growth. By acting systemically, LOX can additionally
contribute to the formation of premetastatic niche (Erler et al.,
2006, 2009). In a mouse model of undifferentiated pleomorphic
sarcoma, a particularly aggressive subtype of sarcomas, hypox-ia-activated HIF-1a induced the expression of procollagen lysyl
oxidase PLOD2, yet another enzyme that stabilizes collagen
cross-links (Eisinger-Mathason et al., 2013). PLOD2 promoted
metastatic dissemination and is clinically associated with poor
prognosis. PLOD2 and the prolyl hydroxylases P4HA1 and
P4HA2 have also been implicated in breast cancer metastasis
(Gilkes et al., 2013a, 2013b).
Other ECM components are also noteworthy. In mouse
models, binding of the ECM glycosaminoglycan hyaluronan to
its cell surface receptor CD44 inhibits apoptosis of breast cancer
cells during lung colonization (Yu et al., 1997). CD44 also func-
tions as a receptor for the ECM glycoprotein osteopontin that
enhances the aggressiveness of glioma stem cells in the perivas-
cular niche (Pietras et al., 2014). CD44 activity promotes the
migration andmetastasis of colorectal cancer stem cells (Todaro
et al., 2014). Moreover, hyaluronan synthase-2 (HAS2), the key
enzyme in hyaluronan biosynthesis, is a significant inducer of
metastasis in mouse models for breast cancer (Li et al., 2007b;
Okuda et al., 2012). High levels of hyaluronan predict poor clin-
ical outcome in breast cancer (Auvinen et al., 2013). The role of
the ECM in metastasis is currently under systematic analysis
and likely to expand in the future (Reticker-Flynn et al., 2012).
Life in the Niche
The current knowledge about the locations and composition of
thenicheswheredisseminatedMetSCs reside is still rudimentary.Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc. 313
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TGF-β
Figure 7. Pathway Amplifiers and Paracrine
Loops for MetSC Support
Many of the known traits that promote metastatic
seeding involve gene products (red) that the
cancer cells express to amplify their own respon-
siveness to vital stromal cues. The cues that acti-
vate these pathways include receptor tyro-
sine kinase (RTK) growth factor ligands (GF),
chemokines like CXCL12, and Wnt and Notch
ligands. Example amplifiers include cell adhesion
receptors like the VCAM1-Ezrin complex that is
engaged by tumor leukocyte integrins; the tyrosine
kinase Src that amplifies PI3K-AKT activation by
CXCR4 and IGF1R (not shown); the cancer-cell-
and myofibroblast-derived ECM components
tenascin C (TNC) and periostin that enhance Wnt
access to their receptors (periostin) or amplify
signaling by the Wnt and Notch pathways (TNC);
and the collagen crosslinking enzymes LOX
and PLOD2 that stiffen the ECM for integrin/focal
adhesion kinase (FAK)-mediated amplification of
RTK signaling. Various cancer-cell-derived cyto-
kines (bottom, red) provide additional support by
recruiting stromal cells that secrete activators
of AKT, MAPK, and STAT3 in incipient meta-
static lesions. MetSC-derived BMP blockers like
Coco protect self-renewal by inhibiting Smad1
signaling.
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that these locations need to support and some insights into the
underlying molecular mechanisms.
Survival on Arrival
Most circulating cancer cells that infiltrate a distant tissue die.
To survive, disseminated cancer cells must avoid exposure to
lethal signals from the reactive stroma, upregulate cell survival
and antiapoptotic pathways to counter the effect of such
signals, or both. One example of the former is the cited case of
brain metastatic cells that express serpins to prevent the mobi-
lization of FasL by plasmin from reactive astrocytes (Valiente
et al., 2014).
The PI3K-AKT pathway is a critical survival input for dissemi-
nated cancer cells. Src activity amplifies the PI3K-AKT response
of breast cancer cells to stromal CXCL12/SDF-1 and IGF1 in the
bone marrow (Figure 7; Zhang et al., 2009). Src activation is
achieved by interaction with the estrogen receptor in luminal
breast cancer cells and is selected for by a CAF-rich stroma in
basal subtype tumors (Zhang et al., 2013b). The endothelial
cell adhesionmolecule VCAM1amplifies the PI3K-AKT response
of breast cancer cells in the lungs (Figure 7). Alpha-4 integrins on
pulmonary macrophages engage VCAM1 on the cancer cells to
trigger Ezrin-dependent amplification of PI3K activation (Chen
et al., 2011b). In these examples, Src and VCAM1 amplify the
ability of metastatic cells to make the most of limited PI3K-
AKT-activating signals in the host stroma. Src activity in breast
tumor clinical samples is associated with bone relapse (Zhang
et al., 2009) and VCAM1 expression with lung relapse (Minn
et al., 2005; Chen et al., 2011b).314 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.Interactions between the receptor
tyrosine kinases EGFR and Met with
ECM-binding integrins enhance metasta-
tic colonization in model systems (Barkan
et al., 2010; Desgrosellier and Cheresh,2010). Results from animal models argue for significant roles of
NF-kB signaling in metastasis of colon, lung, and breast cancers
(Luo et al., 2004; Maeda et al., 2009; Park et al., 2007). JAK-
STAT3 signaling promotes metastasis in melanoma and in
breast, prostate, and pancreatic carcinomas (Abdulghani et al.,
2008; Barbieri et al., 2010; Wei et al., 2003; Xie et al., 2006). An
inherent limitation is that many of these studies were based on
the analysis of general metastatic cell populations, not MetSCs
specifically. However, an example of STAT-driven survival of
MetSCs was described in liver metastasis of colorectal cancer.
MetSCs infiltrating the liver or lungs produced TGF-b that stimu-
lated stromal fibroblasts to produce interleukin-11. In turn, inter-
leukin-11 activated prosurvival signaling through GP130/Stat3
in the cancer cells and facilitated the initiation of liver and lung
metastasis (Figure 7; Calo´n et al., 2012).
Preserving Stemness
Ensuring the self-renewal capacity (‘‘stemness’’) of dissemi-
nated cancer cells, and not just their survival, is a key role of
metastasis niches. Notch and Wnt promote self-renewal within
stem cell niches in the bone marrow (Moore and Lemischka,
2006), the intestinal mucosa (Clevers, 2013), and the brain
(Hambardzumyan et al., 2008), roles that are mirrored in the
regulation of MetSCs in metastatic niches. The involvement of
the Wnt and Notch pathways in supporting the metastasis-initi-
ating capacity of disseminated breast cancer cells, and the role
of ECM molecules like periostin and TNC in this process, have
interesting parallels with the involvement of the PI3K-AKT
pathway in preserving the survival of MetSCs (Zhang et al.,
2009; Chen et al., 2011b). Periostin and TNC in the case of
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PI3K-AKT signaling, act as amplifiers of the ability of MetSCs
to respond to limiting levels of stromal Wnt and Notch ligands
for activation of vital self-renewal pathways.
Reversing EMT
The motility and invasiveness of cancer cells that undergo an
EMT may favor their dispersion to distant organs. Paradoxi-
cally, carcinoma metastases in patients typically present an
epithelial cytology. Recent evidence from experimental sys-
tems shows that cancer cells that underwent an EMT for met-
astatic dissemination must undergo the reverse process, a
mesenchymal-epithelial transition (MET), in order to start meta-
static colonization (refer to Figure 2). In a model of squamous
cell carcinoma, expression of the EMT master regulator Twist
enhanced cancer cell dissemination, but the formation of overt
metastases required a loss of Twist expression and reacquisi-
tion of epithelial traits (Tsai et al., 2012). Similarly, expression
of the EMT transcription factor Prrx-1 promoted tumor dissem-
ination of breast cancer cells whereas the subsequent downre-
gulation of Prrx-1 induced an MET that facilitated metastatic
colonization without suppressing stem cell traits (Ocan˜a et al.,
2012). Id1 promotes metastatic colonization in breast cancer
cells (Gupta et al., 2007) and functions downstream of TGF-b
to suppress Twist expression in basal breast cancer cells
that infiltrate the lung parenchyma (Stankic et al., 2013). What
prompts these cells to respond to TGF-b with an EMT right
before extravasation (Labelle et al., 2011) and with MET right
after is unknown.
Entering and Exiting Dormancy
Metastasis can remain latent for years after the removal of a pri-
mary tumor. Despite the clinical importance of this phenomenon,
little is known about how and why DTCs enter a dormant state,
the different forms that this state may take, the cell-autonomous
and stromal signals that induce and sustain it, and what leads to
the eventual exit from latency for metastatic outgrowth. Most of
the mouse models used for the study of metastasis lack a pro-
longed latency period. This is in contrast to metastasis in the
clinic, where latency is measured in months to years. For these
reasons, it remains unclear whether the metastatic niche com-
ponents and support pathways discussed above are required
before, during, and/or after MetSCs pass through a period of
quiescence. Not much that is based on hard evidence can be
said about these questions.
Most DTCs detected in bone marrow are proliferatively quies-
cent, or ‘‘dormant’’ (Mu¨ller et al., 2005; Pantel et al., 1993).
Although entry into G0 has been regarded as a failure of cancer
cells to proceed with their tumor-propagating potential, in fact
it may represent a defense under adverse conditions (Barkan
et al., 2010; Goss and Chambers, 2010; Klein, 2011). Various
signals and pathways have been implicated in the balance
between dormancy and proliferation in experimental systems
in the few available models. Two mitogen activated kinases
(MAPKs), namely p38 and ERK, control the switch of DTCs be-
tween dormancy and active growth, respectively (Aguirre-Ghiso
et al., 2004). Urokinase receptor (uPAR) induces ERK via alpha5-
beta1 integrins and inhibits p38 (Sosa et al., 2011). BMP signals
in the lung parenchyma have been proposed to enforce latency
in breast cancer cells by suppressing self-renewal and promot-
ing differentiation, with metastatic progression being triggeredby Coco or related BMP-sequestering antagonists (Figure 7;
Gao et al., 2012).
During metastatic latency, cancer cells somehow are able to
evolve and acquire a full complement of metastasis-coloniza-
tion functions that they did not express before. It is difficult to
envision how this progression could occur in DTCs that remain
in a state of replicative quiescence. Although DTCs in bone
marrow look quiescent, the overall DTC population is not static.
Circulating cancer cells can be detected in blood in the
apparent absence of active metastatic disease. If not in the
bone marrow at least in other tissues DTCs may be constantly
exiting and re-entering a dormant state, undergoing further
selection for colonization traits during the active interludes (refer
to Figure 2). Transition between quiescent and proliferative
states is a property of adult stem cells that may be hijacked
by MetSCs.
Toward Overt Colonization
Metastatic cells can aggressively overtake a tissue after they
acquire specialized functions for cooption of local stromal com-
ponents. The clearest example is provided by osteolytic bone
metastasis of breast cancer, by far the most extensively charac-
terized overt metastatic process (Figure 8). Numerous molecu-
lar mediators have been identified that support the ability of
bone metastatic cells to mobilize and activate osteoclasts.
The subjugated osteoclasts aggressively resorb bone matrix,
making room for the growing tumor. Furthermore, osteolysis
causes the release of matrix-stored TGF-b and other growth
factors that further stimulate cancer cells in a feed-forward
cycle of tissue destruction and tumor expansion (Ell and
Kang, 2012; Weilbaecher et al., 2011). Cancer-cell-derived fac-
tors including parathyroid hormone-related protein, interleukins
1, 6, 8, and 11, and TNF-a, proteases including MMP1 and
ADAMTS1, the Notch ligand Jagged1, and cell adhesion mole-
cules VCAM1 and ICAM1, many of which are induced by bone-
derived TGF-b, all converge on osteoclast activation (Ell et al.,
2013; Lu et al., 2011; Sethi et al., 2011; Weilbaecher et al.,
2011).
Osteoclast mobilization traits provide a selective advantage
in the context of bone metastasis but not in primary tumors or
other tissues where there are no osteoclasts to activate or
bone to resorb. Indeed, in experimental models, the acquisition
of some of these traits has been shown to occur after metastatic
cells remained latent for many months, became reactivated,
formed micrometastases in the bone marrow, and were faced
with the need to activate osteoclasts in order to resorb bone
and make room (Lu et al., 2011). This admittedly limited set
of available examples suggests that progression toward overt
colonization involves the acquisition of a final set of metastatic
traits by the progeny of MetSCs that survived arrival and latency
in the host metastatic tissue.
Perspectives
Recent work in this field has aimed at better conceptualizing and
mechanistically explaining the biology of MetSCs. Residual dis-
ease remains challenging to properly model for study, but it
offers a singular opportunity to develop therapeutic interventions
for the suppression of metastasis. Some perspectives on the
origins of metastatic traits have been summarized elsewhere
(Vanharanta and Massague´, 2013). Here we highlight severalCell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc. 315
Figure 8. Toward Overt Colonization
The hematopoietic stem cell (HSC) niche in the
bone marrow is a highly regulated microenvi-
ronment that balances stem cell self-renewal
and differentiation signals. Within the niche,
factors like Ang-1, SCF, TPO, HIF1a, and TGF-b
maintain stem cell quiescence whereas Notch
and Wnt promote self-renewal and proliferation.
BMPs induce expansion of osteoblasts, thereby
indirectly supporting HSCs. The CXCL12-
CXCR4 signaling axis is important for HSC
retention in the niche. In the context of bone
metastasis, breast cancer MetSCs coopt these
cues for survival and to overtake the host
stroma. In the osteolytic process that follows,
the cancer cells stimulate osteoclast differenti-
ation and activation through cancer-cell-derived
cytokines such as IL11 and TNF-a, parathyroid
hormone-related protein (PTHrP), MMP1,
VCAM1, and the Notch ligand Jagged1. Some
of these mediators act directly on osteoclast
precursors to stimulate their maturation. Others
act by stimulating osteoblasts to produce IL6
and RANKL, which in turn stimulate osteoclast
differentiation and activity. Osteoclast-mediated
bone matrix resorption releases TGF-b and
IGF1, which in turn upregulate the expression of
IL11, PTHrP, Jagged1, and other metastasis
mediators in the cancer cells to create a vicious
cycle of relentless bone destruction.
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that seem worthy of attention. They are as follows:
d The phenotypic properties and signaling pathways
required for metastatic outgrowth of disseminated cancer
cells are increasingly being elucidated and overlap with
those of normal stem cells. Although the relationship
between normal stem cells and CSCs is gaining clarity in
many tumor types, the relationship between CSCs and
MetSCs is still enigmatic at present. However, the problem
may be poised for rapid progress.
d A basic conceptual framework for the traits that allow CSC
infiltration and seeding of distant organs is in place. How-
ever, many questions remain about how (genetically or epi-
genetically?),when (in the incipient tumoror in theadvanced
tumor?), and where (at the invasive front or in a distant
organ?) these traits are selected to generate MetSCs.
d The source of MetSCs may depend on the type of cancer.
For each type of cancer, a combination of lineage-tracing
techniques and single-cell analysis in animal models is
needed in order to reveal the relative contribution of mech-
anisms that preserve a CSC phenotype of origin versus
mechanisms that reestablish a stem cell phenotype to
generate MetSCs in disseminated cancer cell populations.
d Metastasis is an intrinsically inefficient process. The evi-
dence suggests that most CSCs that try will fail. Although316 Cell Stem Cell 14, March 6, 2014 ª2014 Elsevier Inc.our knowledge of how the survi-
vors are saved is increasing, very
little is known about what kills the
majority of disseminated cancer
cells. More information on how
the reactive stroma repels infil-
trating cancer cells could yieldclues for how to leverage these mechanisms for thera-
peutic benefit.
d Despite the clinical importance of metastatic latency, little
is known about what induces MetSCs to enter a dormant
state and what allows them to remain viable for years in
this state. Better models are needed in order to determine
what MetSC-supporting pathways are important before,
during, and after the latency phase of metastasis. Killing
latent MetSCs by depriving them of this support seems
more attractive therapeutically than attempting to perpetu-
ally prevent their exit from dormancy.ACKNOWLEDGMENTS
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